NCT02963311View on ClinicalTrials.gov

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

October 8, 2018

Study Completion Date

October 8, 2018

Conditions
Homozygous Familial Hypercholesterolemia
Interventions
DRUG

ALN-PCSSC

ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.

DRUG

Standard of Care

Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.

Trial Locations (3)

2193

Research Site 227001, Parktown

90001

Research Site 201001, Los Angeles

Unknown

Research Site 231001, Amsterdam

Sponsors
All Listed Sponsors
lead

The Medicines Company

INDUSTRY